{"schema_version":"secwatch.filing_event.v1","accession":"0001831868-25-000011","form_type":"8-K/A","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.207973+00:00","generated_at":"2026-05-17T13:23:48.563015+00:00","sec_items":["2.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SeaStar Medical Q2 net loss $2.0M on $0.3M revenue; NEUTRALIZE-AKI trial 60% enrolled","bullets":["Net loss of $2.0M ($0.18/share) vs $3.2M ($1.03/share) in Q2 2024; revenue from QUELIMMUNE pediatric SCD was $0.3M.","NEUTRALIZE-AKI pivotal trial enrollment reached 125 of 200 patients (60%+); interim DSMB recommendations expected Q3 2025.","Added three new top children's hospital customers; SAVE Surveillance Registry showed 75% 28-day survival in first 20 patients.","Raised total $20.8M through offerings in June ($12.4M), July and August 2025 ($8.4M) to extend cash runway into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001831868-25-000011","json":"https://secwatch.observer/filing/0001831868-25-000011.json","markdown":"https://secwatch.observer/filing/0001831868-25-000011.md","text":"https://secwatch.observer/filing/0001831868-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000183186825000011/0001831868-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000183186825000011/icu-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:23:48.563015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}